Torrent-JB Chem Merger Advances as NCLT Issues Clarifying Order

The proposed merger between Torrent Pharmaceuticals and J.B. Chemicals & Pharmaceuticals, valued at approximately ₹25,689 crore, has moved a step closer. The combined entity is expected to generate revenues over ₹15,000 crore, positioning it strongly in India's pharma market.

NCLT Issues Clarifying Order

J.B. Chemicals & Pharmaceuticals (JBCPL) informed the market that the National Company Law Tribunal (NCLT), Ahmedabad Bench, has issued a clarifying order concerning its merger with Torrent Pharmaceuticals. This order, dated March 24, 2026, and uploaded on March 25, 2026, addresses the previously sanctioned merger.

Significance of the Update

The clarification from the NCLT serves as a procedural correction to the Tribunal's earlier approval of the merger. It confirms that the regulatory process is actively progressing and any minor discrepancies are being addressed. This step is vital for the overall advancement of the merger deal.

Background of the Merger Deal

Torrent Pharmaceuticals first announced its intention to acquire a controlling stake in J.B. Chemicals & Pharmaceuticals in June 2025. This involved Torrent purchasing a 46.39% stake from KKR for about ₹11,917 crore. Torrent also launched an open offer to public shareholders and plans to merge JBCPL into its operations.

The deal's equity valuation is around ₹25,689 crore, with a share swap ratio set at 51 Torrent shares for every 100 J.B. Chemicals shares. The merger received approval from the Competition Commission of India (CCI) on October 21, 2025. The entire process is estimated to take 15 to 18 months from the initial announcement.

Impact of the Clarification

This clarifying order from the NCLT addresses specific points within the sanctioning order for the merger. Crucially, it does not change the fundamental terms or the approved share swap ratio. The process is now one step nearer to final regulatory clearances.

Remaining Hurdles

While the NCLT clarification is positive progress, the merger still requires other necessary regulatory approvals. These include consent from SEBI, stock exchanges, and J.B. Chemicals' shareholders. Any further delays in obtaining these approvals could impact the integration timeline.

Market Position After Merger

The combined entity is poised to become a significant player in the Indian pharmaceutical sector, potentially ranking as the 4th largest by prescription volume. This consolidation reflects broader trends in the industry, similar to Sun Pharma's acquisition of Ranbaxy Laboratories, which created a larger, more competitive company.

Key Deal Metrics

• Deal Equity Valuation: Approximately ₹25,689 crore (as of June 2025 announcement).
• Share Swap Ratio: 51 equity shares of Torrent Pharmaceuticals for every 100 equity shares of J.B. Chemicals & Pharmaceuticals (as of June 2025 announcement).
• Projected Combined Revenue: Exceeding ₹15,000 crore (FY25 Pro Forma, as of March 2026 update).
• Projected Combined EBITDA: Over ₹4,800 crore (FY25 Pro Forma, as of March 2026 update).

Next Steps to Watch

• Receipt of final approvals from SEBI and stock exchanges.
• Completion of any remaining shareholder approvals.
• The official closing date of the amalgamation.
• Announcements regarding post-merger integration plans and synergy realization.
• Any further procedural updates from the NCLT or other regulatory bodies.